Page 27 - NON-INVASIVE TESTS FOR EVALUATION OF LIVER DISEASE SEVERITY AND PROGNOSIS
P. 27
Clinical Practice Guidelines liver morphometry in HCV patients with a sustained virological response. J
Hepatol 2013;59:251–256.
[244] Corpechot C, Gaouar F, El Naggar A, Kemgang A, Wendum D, Poupon R, [267] Klibansky DA, Mehta SH, Curry M, Nasser I, Challies T, Afdhal NH. Transient
et al. Baseline values and changes in liver stiffness measured by transient elastography for predicting clinical outcomes in patients with chronic liver
elastography are associated with severity of fibrosis and outcomes of disease. J Viral Hepat 2012;19:e184–e193.
patients with primary sclerosing cholangitis. Gastroenterology 2014;146: [268] Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W,
970–979, quiz e915–e976. et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year
outcomes of patients with chronic hepatitis C. Gastroenterology
[245] Shin NY, Kim MJ, Lee MJ, Han SJ, Koh H, Namgung R, et al. Transient 2011;140:1970–1979, 1979, e1971–e1973.
elastography and sonography for prediction of liver fibrosis in infants with [269] Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term
biliary atresia. J Ultrasound Med 2014;33:853–864. entecavir therapy results in the reversal of fibrosis/cirrhosis and continued
histological improvement in patients with chronic hepatitis B. Hepatology
[246] Bjornsson E, Talwalkar J, Treeprasertsuk S, Neuhauser M, Lindor K. 2010;52:886–893.
Patients with typical laboratory features of autoimmune hepatitis rarely [270] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M,
need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol 2011;9: et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative
57–63. chronic hepatitis B for up to 5 years. Gastroenterology
2006;131:1743–1751.
[247] Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in [271] Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al.
autoimmune hepatitis. Ann Intern Med 1997;127:981–985. Regression of cirrhosis during treatment with tenofovir disoproxil
fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
[248] Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S, Rakhshani N, Lancet 2013;381:468–475.
Tavangar SM, Sohrabpour AA, et al. Reversibility of cirrhosis in autoim- [272] Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, et al.
mune hepatitis. Am J Med 2004;117:125–129. Longitudinal assessment of histology surrogate markers (FibroTest-
ActiTest) during lamivudine therapy in patients with chronic hepatitis B
[249] Romanque P, Stickel F, Dufour JF. Disproportionally high results of transient infection. Am J Gastroenterol 2005;100:1970–1980.
elastography in patients with autoimmune hepatitis. Liver Int [273] Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y.
2008;28:1177–1178. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with
biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis
[250] Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, et al. B virus. J Viral Hepat 2009;16:203–213.
The new paradigm of hepatitis C therapy: integration of oral therapies into [274] Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. On-
best practices. J Viral Hepat 2013;20:745–760. treatment monitoring of liver fibrosis with transient elastography in
chronic hepatitis B patients. Antivir Ther 2011;16:165–172.
[251] EASL Clinical Practice Guidelines: management of chronic hepatitis B virus [275] Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. Significant changes in
infection. J Hepatol 2012;57:167–185. liver stiffness measurements in patients with chronic hepatitis B: 3-year
follow-up study. J Viral Hepat 2011;18:e200–e205.
[252] Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology [276] Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, et al.
2009;50:661–662. Longitudinal assessment of liver stiffness by transient elastography for
chronic hepatitis B patients treated with nucleoside analog. Hepatol Res
[253] Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific 2011;41:1178–1188.
consensus statement on the management of chronic hepatitis B: a 2012 [277] Enomoto M, Mori M, Ogawa T, Fujii H, Kobayashi S, Iwai S, et al. Usefulness
update. Hepatol Int 2012;6:531–561. of transient elastography for assessment of liver fibrosis in chronic
hepatitis B: regression of liver stiffness during entecavir therapy. Hepatol
[254] Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Res 2010;40:853–861.
Biochemical markers of liver fibrosis in patients infected by hepatitis C [278] Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, et al.
virus: longitudinal validation in a randomized trial. J Viral Hepat Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J
2002;9:128–133. Gastroenterol 2011;46:1324–1334.
[279] Lim SG, Cho SW, Lee YC, Jeon SJ, Lee MH, Cho YJ, et al. Changes in liver
[255] Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical stiffness measurement during antiviral therapy in patients with chronic
surrogate markers of liver fibrosis and activity in a randomized trial of hepatitis B. Hepatogastroenterology 2011;58:539–545.
peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481–492. [280] Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, et al. The changes of
liver stiffness and its associated factors for chronic hepatitis B patients with
[256] Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, entecavir therapy. PLoS One 2014;9:e93160.
et al. Serum fibrosis marker levels decrease after successful antiviral [281] Poynard T, Vergniol J, Ngo Y, Foucher J, Thibault V, Munteanu M, et al.
treatment in chronic hepatitis C patients with advanced fibrosis. Clin Staging chronic hepatitis B into seven categories, defining inactive carriers
Gastroenterol Hepatol 2009;7:219–226. and assessing treatment impact using a fibrosis biomarker (FibroTest(R))
and elastography (FibroScan(R)). J Hepatol 2014;61:994–1003.
[257] Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The [282] de Ledinghen V, Vergniol J, Barthe C, Foucher J, Chermak F, Le Bail B, et al.
longitudinal quantitative assessment by transient elastography of chronic Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of
hepatitis C patients treated with pegylated interferon alpha-2b and patients chronically infected with hepatitis B virus. Aliment Pharmacol
ribavirin. Antiviral Res 2009;83:127–134. Ther 2013;37:979–988.
[283] Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, Kim do Y, et al. Prediction of
[258] Vergniol J, Foucher J, Castera L, Bernard PH, Tournan R, Terrebonne E, et al. development of liver-related events by transient elastography in hepatitis
Changes of non-invasive markers and FibroScan values during HCV B patients with complete virological response on antiviral therapy. Am J
treatment. J Viral Hepat 2009;16:132–140. Gastroenterol 2014;109:1241–1249.
[284] Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Increased risk of
[259] Martinez SM, Fernandez-Varo G, Gonzalez P, Sampson E, Bruguera M, hepatocellular carcinoma in chronic hepatitis B patients with transient
Navasa M, et al. Assessment of liver fibrosis before and after antiviral elastography-defined subclinical cirrhosis. Hepatology 2015. http://
therapy by different serum marker panels in patients with chronic dx.doi.org/10.1002/hep.27735.
hepatitis C. Aliment Pharmacol Ther 2011;33:138–148. [285] Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient
elastography for diagnosis of advanced fibrosis and portal hypertension in
[260] Hezode C, Castera L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, patients with hepatitis C recurrence after liver transplantation. Liver
et al. Liver stiffness diminishes with antiviral response in chronic hepatitis Transpl 2006;12:1791–1798.
C. Aliment Pharmacol Ther 2011;34:656–663. [286] Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al.
Liver stiffness measurement predicts severe portal hypertension in
[261] Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, et al. patients with HCV-related cirrhosis. Hepatology 2007;45:1290–1297.
Slow regression of liver fibrosis presumed by repeated biomarkers after
virological cure in patients with chronic hepatitis C. J Hepatol 2013;59:
675–683.
[262] Stasi C, Arena U, Zignego AL, Corti G, Monti M, Triboli E, et al. Longitudinal
assessment of liver stiffness in patients undergoing antiviral treatment for
hepatitis C. Dig Liver Dis 2013;45:840–843.
[263] Vergniol J, Boursier J, Coutzac C, Bertrais S, Foucher J, Angel C, et al.
Evolution of noninvasive tests of liver fibrosis is associated with prognosis
in patients with chronic hepatitis C. Hepatology 2014;60:65–76.
[264] Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z,
et al. Impact of pegylated interferon alfa-2b and ribavirin on liver
fibrosis in patients with chronic hepatitis C. Gastroenterology
2002;122:1303–1313.
[265] Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al.
Histologic improvement of fibrosis in patients with hepatitis C who have
sustained response to interferon therapy. Ann Intern Med 2000;132:
517–524.
[266] D’Ambrosio R, Aghemo A, Fraquelli M, Rumi MG, Donato MF, Paradis V,
et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by
26 Journal of Hepatology 2015 vol. xxx j xxx–xxx
Please cite this article in press as: EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J
Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2015.04.006
Hepatol 2013;59:251–256.
[244] Corpechot C, Gaouar F, El Naggar A, Kemgang A, Wendum D, Poupon R, [267] Klibansky DA, Mehta SH, Curry M, Nasser I, Challies T, Afdhal NH. Transient
et al. Baseline values and changes in liver stiffness measured by transient elastography for predicting clinical outcomes in patients with chronic liver
elastography are associated with severity of fibrosis and outcomes of disease. J Viral Hepat 2012;19:e184–e193.
patients with primary sclerosing cholangitis. Gastroenterology 2014;146: [268] Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W,
970–979, quiz e915–e976. et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year
outcomes of patients with chronic hepatitis C. Gastroenterology
[245] Shin NY, Kim MJ, Lee MJ, Han SJ, Koh H, Namgung R, et al. Transient 2011;140:1970–1979, 1979, e1971–e1973.
elastography and sonography for prediction of liver fibrosis in infants with [269] Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term
biliary atresia. J Ultrasound Med 2014;33:853–864. entecavir therapy results in the reversal of fibrosis/cirrhosis and continued
histological improvement in patients with chronic hepatitis B. Hepatology
[246] Bjornsson E, Talwalkar J, Treeprasertsuk S, Neuhauser M, Lindor K. 2010;52:886–893.
Patients with typical laboratory features of autoimmune hepatitis rarely [270] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M,
need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol 2011;9: et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative
57–63. chronic hepatitis B for up to 5 years. Gastroenterology
2006;131:1743–1751.
[247] Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in [271] Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al.
autoimmune hepatitis. Ann Intern Med 1997;127:981–985. Regression of cirrhosis during treatment with tenofovir disoproxil
fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
[248] Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S, Rakhshani N, Lancet 2013;381:468–475.
Tavangar SM, Sohrabpour AA, et al. Reversibility of cirrhosis in autoim- [272] Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, et al.
mune hepatitis. Am J Med 2004;117:125–129. Longitudinal assessment of histology surrogate markers (FibroTest-
ActiTest) during lamivudine therapy in patients with chronic hepatitis B
[249] Romanque P, Stickel F, Dufour JF. Disproportionally high results of transient infection. Am J Gastroenterol 2005;100:1970–1980.
elastography in patients with autoimmune hepatitis. Liver Int [273] Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y.
2008;28:1177–1178. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with
biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis
[250] Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, et al. B virus. J Viral Hepat 2009;16:203–213.
The new paradigm of hepatitis C therapy: integration of oral therapies into [274] Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. On-
best practices. J Viral Hepat 2013;20:745–760. treatment monitoring of liver fibrosis with transient elastography in
chronic hepatitis B patients. Antivir Ther 2011;16:165–172.
[251] EASL Clinical Practice Guidelines: management of chronic hepatitis B virus [275] Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. Significant changes in
infection. J Hepatol 2012;57:167–185. liver stiffness measurements in patients with chronic hepatitis B: 3-year
follow-up study. J Viral Hepat 2011;18:e200–e205.
[252] Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology [276] Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, et al.
2009;50:661–662. Longitudinal assessment of liver stiffness by transient elastography for
chronic hepatitis B patients treated with nucleoside analog. Hepatol Res
[253] Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific 2011;41:1178–1188.
consensus statement on the management of chronic hepatitis B: a 2012 [277] Enomoto M, Mori M, Ogawa T, Fujii H, Kobayashi S, Iwai S, et al. Usefulness
update. Hepatol Int 2012;6:531–561. of transient elastography for assessment of liver fibrosis in chronic
hepatitis B: regression of liver stiffness during entecavir therapy. Hepatol
[254] Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Res 2010;40:853–861.
Biochemical markers of liver fibrosis in patients infected by hepatitis C [278] Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, et al.
virus: longitudinal validation in a randomized trial. J Viral Hepat Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J
2002;9:128–133. Gastroenterol 2011;46:1324–1334.
[279] Lim SG, Cho SW, Lee YC, Jeon SJ, Lee MH, Cho YJ, et al. Changes in liver
[255] Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical stiffness measurement during antiviral therapy in patients with chronic
surrogate markers of liver fibrosis and activity in a randomized trial of hepatitis B. Hepatogastroenterology 2011;58:539–545.
peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481–492. [280] Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, et al. The changes of
liver stiffness and its associated factors for chronic hepatitis B patients with
[256] Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, entecavir therapy. PLoS One 2014;9:e93160.
et al. Serum fibrosis marker levels decrease after successful antiviral [281] Poynard T, Vergniol J, Ngo Y, Foucher J, Thibault V, Munteanu M, et al.
treatment in chronic hepatitis C patients with advanced fibrosis. Clin Staging chronic hepatitis B into seven categories, defining inactive carriers
Gastroenterol Hepatol 2009;7:219–226. and assessing treatment impact using a fibrosis biomarker (FibroTest(R))
and elastography (FibroScan(R)). J Hepatol 2014;61:994–1003.
[257] Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The [282] de Ledinghen V, Vergniol J, Barthe C, Foucher J, Chermak F, Le Bail B, et al.
longitudinal quantitative assessment by transient elastography of chronic Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of
hepatitis C patients treated with pegylated interferon alpha-2b and patients chronically infected with hepatitis B virus. Aliment Pharmacol
ribavirin. Antiviral Res 2009;83:127–134. Ther 2013;37:979–988.
[283] Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, Kim do Y, et al. Prediction of
[258] Vergniol J, Foucher J, Castera L, Bernard PH, Tournan R, Terrebonne E, et al. development of liver-related events by transient elastography in hepatitis
Changes of non-invasive markers and FibroScan values during HCV B patients with complete virological response on antiviral therapy. Am J
treatment. J Viral Hepat 2009;16:132–140. Gastroenterol 2014;109:1241–1249.
[284] Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Increased risk of
[259] Martinez SM, Fernandez-Varo G, Gonzalez P, Sampson E, Bruguera M, hepatocellular carcinoma in chronic hepatitis B patients with transient
Navasa M, et al. Assessment of liver fibrosis before and after antiviral elastography-defined subclinical cirrhosis. Hepatology 2015. http://
therapy by different serum marker panels in patients with chronic dx.doi.org/10.1002/hep.27735.
hepatitis C. Aliment Pharmacol Ther 2011;33:138–148. [285] Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient
elastography for diagnosis of advanced fibrosis and portal hypertension in
[260] Hezode C, Castera L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, patients with hepatitis C recurrence after liver transplantation. Liver
et al. Liver stiffness diminishes with antiviral response in chronic hepatitis Transpl 2006;12:1791–1798.
C. Aliment Pharmacol Ther 2011;34:656–663. [286] Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al.
Liver stiffness measurement predicts severe portal hypertension in
[261] Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, et al. patients with HCV-related cirrhosis. Hepatology 2007;45:1290–1297.
Slow regression of liver fibrosis presumed by repeated biomarkers after
virological cure in patients with chronic hepatitis C. J Hepatol 2013;59:
675–683.
[262] Stasi C, Arena U, Zignego AL, Corti G, Monti M, Triboli E, et al. Longitudinal
assessment of liver stiffness in patients undergoing antiviral treatment for
hepatitis C. Dig Liver Dis 2013;45:840–843.
[263] Vergniol J, Boursier J, Coutzac C, Bertrais S, Foucher J, Angel C, et al.
Evolution of noninvasive tests of liver fibrosis is associated with prognosis
in patients with chronic hepatitis C. Hepatology 2014;60:65–76.
[264] Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z,
et al. Impact of pegylated interferon alfa-2b and ribavirin on liver
fibrosis in patients with chronic hepatitis C. Gastroenterology
2002;122:1303–1313.
[265] Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al.
Histologic improvement of fibrosis in patients with hepatitis C who have
sustained response to interferon therapy. Ann Intern Med 2000;132:
517–524.
[266] D’Ambrosio R, Aghemo A, Fraquelli M, Rumi MG, Donato MF, Paradis V,
et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by
26 Journal of Hepatology 2015 vol. xxx j xxx–xxx
Please cite this article in press as: EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J
Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2015.04.006
